Kottayil v. Insys Therapeutics, Inc.

BVLaw
Full Text of Court Cases
August 29, 2017

Access the Full Article

This article and its downloads are available with a subscription to any of these products:
Already a subscriber?  Login
This article is also available for purchase. (13,769 words)   Add to Cart >>
Need help? Contact us:
1-503-479-8200 ext 2 or sales@bvresources.com
8731 Commercial Physical and Biological Research
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
shareholder dissent/oppression
damages, expert testimony, fair value, breach of fiduciary duty, discount for lack of marketability (DLOM), discounted cash flow (DCF), entire fairness, fraud, minority discount, projections, valuation methods, initial public offering (IPO)
Kottayil v. Insys Therapeutics, Inc.
2017 Ariz. App. Unpub. LEXIS 1179
US
State Court
Arizona
Court of Appeals
Unknown (plaintiff); unknown (defendants)
Jones

Summary

In shareholder suit involving pharmaceutical startup with uncertain prospects, appeals court upholds trial court’s rejection of expert testimony based on “traditional” valuation methods in favor of noncontemporary IPO valuation to determine fair value.
Kottayil v. Insys Therapeutics, Inc.
PDF, Size: 535 KB

See Also

Court Validates Use of IPO Valuation in Fair Value Proceeding

Court Case Digests
August 29, 2017

In shareholder suit involving pharmaceutical startup with uncertain prospects, appeals court upholds trial court’s rejection of expert testimony based on “traditional” valuation methods in favor of noncontemporary IPO valuation to determine fair value.